In September 2013, the FDA released new labeling pointers for very long acting and extended launch opioids necessitating manufacturers to remove average soreness as indicator for use, rather stating the drug is for "ache severe adequate to require day-to-day, around-the-clock, long run opioid therapy".Fuelling another technology of groundbreaking i